Limiting the analysis to samples from individuals all of whom had HER2+ invasive breast cancer enabled us to match for any theoretical differences in the ipsilateral high-risk cells that might be associated with development of HER2+ breast cancer. This evidence concerns the gene ERBB2 and invasive breast carcinoma.